1. Home
  2. SPOK vs DRUG Comparison

SPOK vs DRUG Comparison

Compare SPOK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPOK
  • DRUG
  • Stock Information
  • Founded
  • SPOK 2004
  • DRUG 2019
  • Country
  • SPOK United States
  • DRUG United States
  • Employees
  • SPOK N/A
  • DRUG N/A
  • Industry
  • SPOK Telecommunications Equipment
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • SPOK Telecommunications
  • DRUG Health Care
  • Exchange
  • SPOK Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • SPOK 379.1M
  • DRUG 364.8M
  • IPO Year
  • SPOK 1992
  • DRUG N/A
  • Fundamental
  • Price
  • SPOK $13.90
  • DRUG $56.97
  • Analyst Decision
  • SPOK
  • DRUG Strong Buy
  • Analyst Count
  • SPOK 0
  • DRUG 9
  • Target Price
  • SPOK N/A
  • DRUG $81.67
  • AVG Volume (30 Days)
  • SPOK 174.5K
  • DRUG 196.2K
  • Earning Date
  • SPOK 10-29-2025
  • DRUG 12-30-2025
  • Dividend Yield
  • SPOK 8.99%
  • DRUG N/A
  • EPS Growth
  • SPOK 12.68
  • DRUG N/A
  • EPS
  • SPOK 0.80
  • DRUG N/A
  • Revenue
  • SPOK $139,739,000.00
  • DRUG N/A
  • Revenue This Year
  • SPOK $4.11
  • DRUG N/A
  • Revenue Next Year
  • SPOK $2.63
  • DRUG N/A
  • P/E Ratio
  • SPOK $17.37
  • DRUG N/A
  • Revenue Growth
  • SPOK 1.47
  • DRUG N/A
  • 52 Week Low
  • SPOK $13.24
  • DRUG $23.18
  • 52 Week High
  • SPOK $19.31
  • DRUG $70.23
  • Technical
  • Relative Strength Index (RSI)
  • SPOK 34.52
  • DRUG 49.89
  • Support Level
  • SPOK $13.24
  • DRUG $55.01
  • Resistance Level
  • SPOK $13.99
  • DRUG $61.81
  • Average True Range (ATR)
  • SPOK 0.45
  • DRUG 3.80
  • MACD
  • SPOK 0.01
  • DRUG -0.06
  • Stochastic Oscillator
  • SPOK 20.59
  • DRUG 61.06

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: